Carol J. Fabian, MD
Director, Breast Cancer Prevention and Survivorship Research Center, Medical Oncology
Mark and Bette Morris Family Professorship in Cancer Prevention, Mark and Bette Morris Foundationcfabian@kumc.edu
Dr. Carol Fabian is a breast medical oncologist and a University Distinguished Professor at the University of Kansas Medical Center. She received her medical degree from the University of Kansas in 1972, and fellowship in Medical Oncology at the University of Kansas in 1977. She is board certified in both Internal Medicine and Medical Oncology. She has been on the faculty in the Division of Medical Oncology since 1977 and has served in multiple capacities including Medical Director of the Cancer Center, Founder and Director of the Breast Cancer Prevention and Survivorship Research Center, Leader or co-Leader of the Cancer Prevention Program, and Associate Director of Clinical Research in the NCI Designated Cancer Center.
Education and Training
- BA, Univ. of Kansas
- MD, Univ. of Kansas-Medical Ctr.
- Internship, Internal Medicine, Wesley Medical Center, Wichita, KS
- Residency, Internal Medicine, Wesley Medical Center, Wichita, KS
- Clinical Fellowship, Clinical Oncology, University of Kansas Medical Center, Kansas City, KS
Licensure, Accreditations & Certifications
- City of Hope, City of Hope Genetic Training
- Clinical Oncology Certification, American Board of Clinical Oncology
- Internal Medicine Certification, American Board of Internal Medicine
- Medical License, Kansas Board of Healing Arts
- Medical License, Missouri Board of Healing Arts
- American Association for Cancer Research, Member, 1978 - Present
- American Society of Clinical Oncology, Member, 1978 - Present
- Southwest Oncology Group, Member, 1977 - Present
Dr. Fabian’s early research was primarily in breast cancer treatment but for the past 25 years the research focus has been primarily in breast cancer prevention and survivorship. Currently her clinic practice is confined to breast cancer risk assessment and which includes genetic testing, and prevention. Prevention encompasses advice on supplemental screening, lifestyle, hormone replacement and alternatives, and standard and clinical trial approaches to risk reduction. Dr. Fabian and her team have focused on evaluating prevention interventions which are likely to be effective but unlikely to negatively impact quality of life. Recently these have including for premenopausal women lignans, omega-3 fatty acids, and novel selective estrogen receptor modulators, and for postmenopausal women tissue selective estrogen complexes, omega-3 fatty acids, and behavioral weight loss interventions. She developed a minimally invasive technique for sampling benign breast tissue called random periareolar fine needle aspiration (RPFNA) which has subsequently been used by multiple investigators in early phase prevention clinical trials to assess gene and protein expression changes with the intervention. The biomarker investigational work and translational early phase trials have been supported by our ~$20 million in federal and $3 million in foundation direct cost funding for which Dr. Fabian was PI. She has ~ 167 peer-reviewed manuscripts plus invited reviews editorials and book chapters. A full listing is available in MyBibliography: http://www.ncbi.nlm.nih.gov/myncbi/browse/collection/47845155/.
National Research Service
Dr. Fabian currently serves as the site PI and on the executive committees of two NCI funded Early Clinical Prevention Trial Consortia, (Northwestern and University of Michigan) with her primary aim of mentoring young clinicians to develop and conduct Phase I and II prevention trials. She is a Fellow of the American Society of Clinical Oncology. She has previously co-chaired the SWOG Cancer Survivorship committee, chaired ASCO’s Prevention committee, and the Prevention Workforce Pipeline, co-chaired ASCO’s Pharmacologic Interventions for Breast Cancer Risk Reduction (2019), and served on ASCOs committees which developed Position Statements on Obesity, as well as Prevention and Monitoring of Cardiac Dysfunction in Cancer Survivors. She is currently a Fellow of the American Society of Clinical Oncology.
Current Research and Grants
- Biomarker-Based Phase IIB Trial of Bazedoxifene-Conjugated Estrogen to Reduce Risk for Breast Cancer, NIH/NCI R01 CA249437-01A1, PI, PI
- Early Phase Clinical Cancer Prevention Consortium, NIH/NCI via University of Michigan UG1 CA242632-01A1
- Fabian, C., J, Befort, C, Phillips, T., A, Nydegger, J., L, Kreutzjans, A, Powers, K., R, Metheny, T, Klemp, J., R, Carlson, S, Sullivan, D., K, Zalles, C, Giles, E, Hursting, S., D, Kimler, B., F. 2021. Change in Blood and Benign Breast Biomarkers in Women Undergoing a Weight Loss Intervention Randomized to High Dose Omega 3 Fatty Acids vs Placebo. Cancer Prevention Research, 14 (9), 893-904
- Fabian, Carol., J. 2021. Tamoxifen: Will Less Equal More in Women with Precancerous Breast Disease?. Clinical Cancer Research, 27 (13), 3510-3511
- Fabian, Carol., J, Khan, S., A, Garber, J., E, Dooley, W., C, Yee, L., D, Klemp, Jennifer., R, Nydegger, Jennifer., L, Powers, Kandy., R, Kreutzjens, Amy., L, Zalles, C., M, Metheny, T, Phillips, T., A, Hu, J, Koestler, D., C, Chalise, P, Yellapu, Kumar, Jernigan, C, Petroff, B., K, Hursting, S., D, Kimler, Bruce., F. 2020. Randomized Phase IIB Trial of the LIgnan Secoisolariciresinol Diglucoside in Pre-Menopausal Women at Increased Risk for Development of Breast Cancer. Cancer Prevention Research, 13 (7), 623-634
- Befort, C., A, Kimler, Bruce., F, Bantis, L., E, Phillips, T., A, Fabian, Carol., J. 2020. Effects of Weight Loss and Weight Regain on Circulating Biomarkers in Overweight/Obese Breast Cancer Survivors Enrolled in a Weight Loss Trial in the Rural Midwest. Cancer Epidemiol Biomarkers Prev, 29 (7), 1321-1328
- Fabian, Carol., J, Nye, Lauren., E, Powers, Kandy., R, Nydegger, Jennifer., L, Kreutzjans, Amy., L, Phillips, T., A, Metheny, T, Winblad, O, Zalles, C., M, Hagan, C., R, Goodman, M., L, Gaiewski, B., J, Koestler, D., C, Chalise, P, Kimler, Bruce., F. 2019. Effect of Bazedoxifene and Conjugated Estrogen (Duavee) on Breast Cancer Biomarkers in High-Risk Women: a Pilot Study. Cancer Prevention Research, 12 (10), 711-720
- Visvanathan, K, Fabian, Carol., J, Bantug, E, Brewster, A., M, Davidson, N., E, DeCensi, A, Floyd, J., D, Garber, J., E, Hofstatter, E., W, Khan, S., A, Katapodi, M., C, Pruthi, S, Raab, R, Runowicz, C., D, Somerfield, M., R. 2019. Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. J Clin Oncol, 20;37(33), 3152-3165
- Fabian, C., J, Klemp, J., R, Marchello, N, Vidoni, E., D, Sullivan, D., K, Nydegger, J., L, Phillips, T., A, Kreutzjans, A., L, Hendry, B, Befort, C., A, Nye, L., E, Powers, K., R, Hursting, S., D, Giles, E., D, Hamilton-Reeves, J., M, Li, B, Kimler, B., F. 2021. Rapid Escalation of High-Volume Exercise During Caloric Restriction; Change in Visceral Adipose Tissue and Adipocytokines in Obese, Sedentary Breast Cancer Survivors. Cancers, 13 (19), 4871